Skip to main content
New GLP-1 protocol guide just published Read →
Two founders in conversation across a desk reviewing a research paper
§ 08 The Manifesto

About Peptidely.

An independent educational resource built for a peptide space where marketing often outruns evidence and regulatory clarity.

The peptide therapy space contains some genuinely interesting science and an enormous amount of confusion. Peptidely exists to make that middle ground usable.
— Peptidely · Editor's note
§ 01 Position

We organize the
middle ground.

We organize compounds by evidence level, regulatory status, and health application so the site behaves more like a research map than a product funnel.

We document landmark clinical trials, explain the regulatory landscape plainly, and provide practical resources for evaluating therapy options critically.

We do not sell peptides, refer to suppliers, or run advertising that compromises editorial independence.

§ 02 Editorial Principles

What the site
optimizes for.

Five editorial guardrails. They keep the rest of the product coherent and steer every decision about what to publish.

  1. 01

    Evidence first

    We distinguish randomized controlled trials, animal models, and anecdote instead of flattening them into one narrative.

  2. 02

    Regulatory honesty

    We document what is and is not legally accessible, including the compounding constraints that changed after 2023.

  3. 03

    No false balance

    We do not give equal weight to a Phase III trial and a user report. Evidence quality matters.

  4. 04

    Updated content

    The regulatory and research landscape changes. We update content when the facts change.

  5. 05

    No medical advice

    The site exists to support better conversations with clinicians, not to replace them.

§ 03 Coverage

What we cover.

The site is broader than a molecule directory — it combines evidence, regulation, sourcing, and practical tools.

01

Compound profiles

Profiles spanning approved drugs, off-label clinical use, and research compounds.

02

Clinical evidence

Landmark trials, evidence levels, and plain-language summaries of what the data actually shows.

03

Regulatory landscape

Approval status, compounding rules, and the access constraints shaping the field.

04

Safety & sourcing

COA interpretation, supplier evaluation, endotoxin testing, and harm-reduction basics.

05

Conditions hub

Peptide research organized by health application, not just by molecule name.

06

Practical tools

Dose calculator, reconstitution guidance, compound finder, and regulatory tracking.

Continue exploring

The best way to understand the editorial approach is to move between the structured reference pages and the longer explanatory guides.